Radiation therapy of the nervous system

Amy Pruitt; Donald E. Thrall

doi:10.22233/9781910443125.24

British Small Animal Veterinary Association , 470 (2013); https://doi.org/10.22233/9781910443125.24

/content/chapter/10.22233/9781910443125.chap24

Radiation therapy of the nervous system

GBP

BSAVA Library Pass Buy a pass

Authors: Amy Pruitt and Donald E. Thrall
From: BSAVA Manual of Canine and Feline Neurology
Item: Chapter 24, pp 470 - 480
DOI: 10.22233/9781910443125.24
Copyright: © 2013 British Small Animal Veterinary Association
Publication Date: January 2013

Abstract

With the common use of computed tomography (CT) and magnetic resonance imaging (MRI) for assessing brain and spinal cord disease, more informed decisions can be made regarding potential therapeutic interventions. This chapters deals with prescribing a radiation dose, reported studies, palliative irradiation, future directions.

Preview this chapter:

Full text loading...

/content/chapter/10.22233/9781910443125.chap24

Figures

/content/figure/10.22233/9781910443125.chap24.fig24_1

24.1

Sagittal T2-weighted MR images of three different brain tumours that have similar characteristics. The lesions are all reasonably well defined, isointense to hyperintense compared with the surrounding parenchyma, and mass like. (a) Grade 2 oligodendroglioma. (b) Meningioma. (c) Choroid plexus papilloma. (Courtesy of S Platt) © 2013 British Small Animal Veterinary Association

10.22233/9781910443125/fig24_1_thumb.gif

10.22233/9781910443125/fig24_1.png

24.1 Sagittal T2-weighted MR images of three different brain tumours that have similar characteristics. The lesions are all reasonably well defined, isointense to hyperintense compared with the surrounding parenchyma, and mass like. (a) Grade 2 oligodendroglioma. (b) Meningioma. (c) Choroid plexus papilloma. (Courtesy of S Platt)

/content/figure/10.22233/9781910443125.chap24.fig24_2

24.2

Cumulative probability of survival as a function of time after treatment for canine meningioma treated with surgery alone (black line) or surgery followed by irradiation (blue line). Median survival times are 7.0 and 16.5 months, respectively, suggesting a role for postoperative irradiation in canine meningioma patients. *= censored data point. (Reproduced from Axlund et al. (2002) with permission from the Journal of the American Veterinary Medical Association) © 2013 British Small Animal Veterinary Association

10.22233/9781910443125/fig24_2_thumb.gif

10.22233/9781910443125/fig24_2.png

24.2 Cumulative probability of survival as a function of time after treatment for canine meningioma treated with surgery alone (black line) or surgery followed by irradiation (blue line). Median survival times are 7.0 and 16.5 months, respectively, suggesting a role for postoperative irradiation in canine meningioma patients. *= censored data point. (Reproduced from Axlund et al. (2002) with permission from the Journal of the American Veterinary Medical Association)

/content/figure/10.22233/9781910443125.chap24.fig24_3

24.3

Progression-free survival (PFS) as a function of time after treatment for canine meningioma based on the proliferative capacity of the tumour. Survival times of dogs with rapidly proliferating tumours (blue line) are shorter than those of dogs with slowly proliferating tumours (black line). Proliferative capacity was based on immunohistochemical quantification of PCNA. (Reproduced from Theon et al. (2000) with permission from the Journal of the American Veterinary Medical Association) © 2013 British Small Animal Veterinary Association

10.22233/9781910443125/fig24_3_thumb.gif

10.22233/9781910443125/fig24_3.png

24.3 Progression-free survival (PFS) as a function of time after treatment for canine meningioma based on the proliferative capacity of the tumour. Survival times of dogs with rapidly proliferating tumours (blue line) are shorter than those of dogs with slowly proliferating tumours (black line). Proliferative capacity was based on immunohistochemical quantification of PCNA. (Reproduced from Theon et al. (2000) with permission from the Journal of the American Veterinary Medical Association)

/content/figure/10.22233/9781910443125.chap24.fig24_4

24.4

Progression-free survival (PFS) as a function of time after irradiation of canine pituitary macrotumours. Survival times are shorter in dogs with large tumours (blue line) than in dogs with small tumours (black line). Tumour size was characterized as relative tumour size, defined as the largest tumour area visible on CT or MRI, divided by the area of the cranial cavity at that level. (Reproduced from Theon and Feldman (1998) with permission from the Journal of the American Veterinary Medical Association) © 2013 British Small Animal Veterinary Association

10.22233/9781910443125/fig24_4_thumb.gif

10.22233/9781910443125/fig24_4.png

24.4 Progression-free survival (PFS) as a function of time after irradiation of canine pituitary macrotumours. Survival times are shorter in dogs with large tumours (blue line) than in dogs with small tumours (black line). Tumour size was characterized as relative tumour size, defined as the largest tumour area visible on CT or MRI, divided by the area of the cranial cavity at that level. (Reproduced from Theon and Feldman (1998) with permission from the Journal of the American Veterinary Medical Association)

/content/figure/10.22233/9781910443125.chap24.fig24_5

24.5

Progression-free survival (PFS) as a function of time after irradiation of canine pituitary macrotumours. Survival times are shorter in dogs with endocrinologically inactive tumours (blue line) than in dogs with active tumours (black line). (Reproduced from Theon and Feldman (1998) with permission from the Journal of the American Veterinary Medical Association) © 2013 British Small Animal Veterinary Association

10.22233/9781910443125/fig24_5_thumb.gif

10.22233/9781910443125/fig24_5.png

24.5 Progression-free survival (PFS) as a function of time after irradiation of canine pituitary macrotumours. Survival times are shorter in dogs with endocrinologically inactive tumours (blue line) than in dogs with active tumours (black line). (Reproduced from Theon and Feldman (1998) with permission from the Journal of the American Veterinary Medical Association)

/content/figure/10.22233/9781910443125.chap24.fig24_6

24.6

Survival times of dogs with pituitary masses treated with either radiation therapy (blue line) or left untreated (black line). Radiation treatment was given to 19 dogs and 27 dogs received no treatment. The lines are significantly different (log-rank test: P5 .0039). Censored dogs are indicated by vertical marks. (Reproduced from Kent et al. (2007) with permission from the Journal of Veterinary Internal Medicine) © 2013 British Small Animal Veterinary Association

10.22233/9781910443125/fig24_6_thumb.gif

10.22233/9781910443125/fig24_6.png

24.6 Survival times of dogs with pituitary masses treated with either radiation therapy (blue line) or left untreated (black line). Radiation treatment was given to 19 dogs and 27 dogs received no treatment. The lines are significantly different (log-rank test: P5 .0039). Censored dogs are indicated by vertical marks. (Reproduced from Kent et al. (2007) with permission from the Journal of Veterinary Internal Medicine)